These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36204307)

  • 1. Genome-wide analysis of the FOXA1 transcriptional regulatory network identifies super enhancer associated LncRNAs in tamoxifen resistance.
    Zhang X; Zhang Q; Liu G
    Front Genet; 2022; 13():992444. PubMed ID: 36204307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
    Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
    Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
    [No Abstract]   [Full Text] [Related]  

  • 3. FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer.
    Fu X; Pereira R; De Angelis C; Veeraraghavan J; Nanda S; Qin L; Cataldo ML; Sethunath V; Mehravaran S; Gutierrez C; Chamness GC; Feng Q; O'Malley BW; Selenica P; Weigelt B; Reis-Filho JS; Cohen O; Wagle N; Nardone A; Jeselsohn R; Brown M; Rimawi MF; Osborne CK; Schiff R
    Proc Natl Acad Sci U S A; 2019 Dec; 116(52):26823-26834. PubMed ID: 31826955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inference of hierarchical regulatory network of estrogen-dependent breast cancer through ChIP-based data.
    Gu F; Hsu HK; Hsu PY; Wu J; Ma Y; Parvin J; Huang TH; Jin VX
    BMC Syst Biol; 2010 Dec; 4():170. PubMed ID: 21167036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
    Yamaguchi N; Nakayama Y; Yamaguchi N
    J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and Analysis of Estrogen Receptor
    Zhang X; Gao S; Li Z; Wang W; Liu G
    Biomed Res Int; 2020; 2020():9031723. PubMed ID: 32420379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
    Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
    BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.
    Droog M; Nevedomskaya E; Kim Y; Severson T; Flach KD; Opdam M; Schuurman K; Gradowska P; Hauptmann M; Dackus G; Hollema H; Mourits M; Nederlof P; van Boven H; Linn SC; Wessels L; van Leeuwen FE; Zwart W
    Cancer Res; 2016 Jul; 76(13):3773-84. PubMed ID: 27197147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet.
    McCune K; Bhat-Nakshatri P; Thorat MA; Nephew KP; Badve S; Nakshatri H
    Cancer Res; 2010 Jan; 70(2):685-96. PubMed ID: 20068169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-Wide Analysis of the FOXA1 Transcriptional Network Identifies Novel Protein-Coding and Long Noncoding RNA Targets in Colorectal Cancer Cells.
    Lazar SB; Pongor L; Li XL; Grammatikakis I; Muys BR; Dangelmaier EA; Redon CE; Jang SM; Walker RL; Tang W; Ambs S; Harris CC; Meltzer PS; Aladjem MI; Lal A
    Mol Cell Biol; 2020 Oct; 40(21):. PubMed ID: 32839292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells.
    Li F; Miao L; Xue T; Qin H; Mondal S; Thompson PR; Coonrod SA; Liu X; Zhang X
    J Exp Clin Cancer Res; 2019 Oct; 38(1):414. PubMed ID: 31601253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
    PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2 inhibition sensitizes tamoxifen‑resistant breast cancer cells through cell cycle regulation.
    Chen S; Yao F; Xiao Q; Liu Q; Yang Y; Li X; Jiang G; Kuno T; Fang Y
    Mol Med Rep; 2018 Feb; 17(2):2642-2650. PubMed ID: 29207119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOX4-mediated FBW7 transcriptional upregulation confers Tamoxifen resistance in ER+ breast cancers via GATA3 downregulation.
    Sharma A; Thacker G; Mishra M; Singh AK; Upadhyay V; Sanyal S; Trivedi AK
    Life Sci; 2022 Aug; 303():120682. PubMed ID: 35662647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HOXB5 Confers Tamoxifen Resistance in Breast Cancer Cells and Promotes Tumor Aggression and Progression.
    Kim CY; Kim YC; Oh JH; Kim MH
    Anticancer Res; 2021 Jul; 41(7):3409-3417. PubMed ID: 34230136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
    Fu X; Jeselsohn R; Pereira R; Hollingsworth EF; Creighton CJ; Li F; Shea M; Nardone A; De Angelis C; Heiser LM; Anur P; Wang N; Grasso CS; Spellman PT; Griffith OL; Tsimelzon A; Gutierrez C; Huang S; Edwards DP; Trivedi MV; Rimawi MF; Lopez-Terrada D; Hilsenbeck SG; Gray JW; Brown M; Osborne CK; Schiff R
    Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6600-E6609. PubMed ID: 27791031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
    Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
    BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The LncRNA HOTAIRM1 Promotes Tamoxifen Resistance by Mediating HOXA1 Expression in ER+ Breast Cancer Cells.
    Kim CY; Oh JH; Lee JY; Kim MH
    J Cancer; 2020; 11(12):3416-3423. PubMed ID: 32284737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated Chromatin Accessibility and Transcriptome Landscapes of Doxorubicin-Resistant Breast Cancer Cells.
    Wang X; Yan J; Shen B; Wei G
    Front Cell Dev Biol; 2021; 9():708066. PubMed ID: 34395436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.